Free

Free

Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles with SEC Over Shorting Dendreon Stock

The lead author of a paper that argued that the prostate cancer immunotherapy Provenge endangered lives of cancer patients has entered a settlement agreement with the Securities and Exchange Commission. The agreement states that Marie Huber, an analyst at a hedge fund, had prepared and anonymously circulated a paper about Provenge (sipuleucel-T) at a time […]
Free

BTCL Medenica

Controversial Dr. Rajko Medenica Sued By Patient;Hilton Head Hospital Reviews His PracticesRajko Medenica, a controversial Hilton Head, SC, physician whose healing talents are lauded by well-connected patients but rarely published in peer reviewed literature, is facing a civil suit stemming from management of a node negative breast cancer patient.
Free

BTCL NCI Budget

NCI Intramural Budget: Well-Funded Labs, High Costs, Or Deceiving Appearances?Item: On average, an NCI laboratory or branch chief controls more than $4 million per year.
Free

BTCL P-32

P-32 Ingestion At NCI Attracts Attention; Similar Cases Seen At Labs In The PastFollowing months of press coverage, the story that began when a postdoctoral researcher at NCI received an internal dose of phosphorus-32 is continuing to attract national attention.
Free

BTCL Burzynski

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy DataClinical trials of “antineoplastons” therapy are unlike any other in modern medicine.
Free

BTCL Imclone

FDA Says ImClone Data Insufficient To Evaluate Colorectal Cancer Drug C225FDA last week declined to review the application by ImClone Systems Inc. for C225, a treatment for colorectal cancer patients who develop progressive disease following treatment with CPT-11.